Sanofi Operating Expenses 2012-2026 | SNY
Sanofi annual/quarterly operating expenses history and growth rate from 2012 to 2026. Operating expenses can be defined as the sum of all operating expenses for the given industry.
- Sanofi operating expenses for the quarter ending March 31, 2026 were $10.719B, a 22.77% increase year-over-year.
- Sanofi operating expenses for the twelve months ending March 31, 2026 were $45.012B, a 18.78% increase year-over-year.
- Sanofi annual operating expenses for 2025 were $43.024B, a 8.37% increase from 2024.
- Sanofi annual operating expenses for 2024 were $39.702B, a 2.39% decline from 2023.
- Sanofi annual operating expenses for 2023 were $40.673B, a 9.63% increase from 2022.
|
Sanofi Annual Operating Expenses (Millions of US $) |
|
|---|---|
| 2025 | $43,024 |
| 2024 | $39,702 |
| 2023 | $40,673 |
| 2022 | $37,101 |
| 2021 | $36,502 |
| 2020 | $26,298 |
| 2019 | $34,877 |
| 2018 | $35,902 |
| 2017 | $33,851 |
| 2016 | $30,815 |
| 2015 | $31,672 |
| 2014 | $36,807 |
| 2013 | $36,033 |
| 2012 | $37,697 |
| 2011 | $38,384 |
|
Sanofi Quarterly Operating Expenses (Millions of US $) |
|
|---|---|
| 2026-03-31 | $10,719 |
| 2025-12-31 | $12,975 |
| 2025-09-30 | $11,073 |
| 2025-06-30 | $10,245 |
| 2025-03-31 | $8,730 |
| 2024-12-31 | $6,975 |
| 2024-09-30 | $11,363 |
| 2024-06-30 | $10,826 |
| 2024-03-31 | $10,538 |
| 2023-12-31 | $11,762 |
| 2023-09-30 | $10,318 |
| 2023-06-30 | $9,609 |
| 2023-03-31 | $8,984 |
| 2022-12-31 | $9,789 |
| 2022-09-30 | $8,924 |
| 2022-06-30 | $9,798 |
| 2022-03-31 | $8,590 |
| 2021-09-30 | $9,190 |
| 2021-06-30 | |
| 2021-03-31 | $8,186 |
| 2020-09-30 | $8,621 |
| 2020-03-31 | $7,940 |
| 2019-09-30 | $8,516 |
| 2019-03-31 | $8,358 |
| 2018-03-31 | $8,440 |
| 2017-12-31 | $9,384 |
| 2017-09-30 | $8,606 |
| 2017-06-30 | $8,232 |
| 2017-03-31 | $7,630 |
| 2016-12-31 | $8,062 |
| 2016-09-30 | $7,651 |
| 2016-06-30 | $7,661 |
| 2016-03-31 | $7,441 |
| 2015-09-30 | $8,462 |
| 2015-06-30 | $8,335 |
| 2014-06-30 | $9,198 |
| 2013-06-30 | $9,015 |
| 2012-06-30 | $9,533 |
| 2012-03-31 | $8,666 |
| 2011-12-31 | $9,654 |
| 2011-09-30 | $9,903 |
| 2011-06-30 | $10,465 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $114.048B | $49.347B |
| Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |